KR840008818A - 재조합 벡큘로비루스 표현 벡터의 제조방법 - Google Patents

재조합 벡큘로비루스 표현 벡터의 제조방법 Download PDF

Info

Publication number
KR840008818A
KR840008818A KR1019840002931A KR840002931A KR840008818A KR 840008818 A KR840008818 A KR 840008818A KR 1019840002931 A KR1019840002931 A KR 1019840002931A KR 840002931 A KR840002931 A KR 840002931A KR 840008818 A KR840008818 A KR 840008818A
Authority
KR
South Korea
Prior art keywords
baculovirus
gene
promoter
recombinant
selection
Prior art date
Application number
KR1019840002931A
Other languages
English (en)
Other versions
KR910009203B1 (ko
Inventor
이. 스미스 게일 (외1)
Original Assignee
아더 지. 한센
더텍사스 에이 앤드 엠유리버시티 시스템
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US06/498,858 external-priority patent/US4745051A/en
Application filed by 아더 지. 한센, 더텍사스 에이 앤드 엠유리버시티 시스템 filed Critical 아더 지. 한센
Publication of KR840008818A publication Critical patent/KR840008818A/ko
Priority to KR1019900001372A priority Critical patent/KR920001368B1/ko
Application granted granted Critical
Publication of KR910009203B1 publication Critical patent/KR910009203B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14151—Methods of production or purification of viral material

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

내용 없음

Description

재조합 벡큘로비루스 표현 벡터의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 전이벡터, pAc101의 구성에 대한 도식을 나타낸다. 제2도는 변환전이 벡터 pAc311, pAc360, pAc373, pAc380을 구성하는 도식을 나타낸다. 제3도는 AcMNPV의 폴리헤드린 유전 자의 부분적인 뉴클레오티드 배열과 그 유전자 상부의 배열을 나타낸다.

Claims (33)

  1. 벡큘로비루스 유전자 또는 그부분을 함유하는 DNA 분체(단편)를 제조하기 위하여 벡큘로비루스 DNA를 절단시키고 상기 DNA 단편을 클로닝 운반자내로 삽입시킨후 선택유전자 또는 그 부분중의 최소한 하나를 변화된 클로닝 운반자내로 삽입시켜 상기의 선택유전자 또는 그부분이 벡큘로비루스 유전자의 프로모터 또는 그자신의 프로모터의 전사조절을 받으며, 재조합을 유발시켜 재조합과 비재조합의 벡큘로비루스의 혼합물을 제조하기 위하여 상기 재제합 전이 벡터를 벡큘로비루스 DNA와 접촉시키며 그 혼합물로부터 재조합 벡큘로비루스 표현벡터를 분리시킴을 특징으로하는, 숙주 곤충세포 내에서 선택유전자 또는 그부분을 표현할 수 있는 재조합벡큘로비루스 표현벡터를 제조하는 방법.
  2. 제1항에 있어서 선택유전자 또는 그부분이 초소한 일부분의 벡큘로비루스유전자에 대치되어 클로닝 운반자내로 삽입되는 방법.
  3. 제1항에 있어서 벡큘로비루스유전자가 폴리헤드린 프로모터를 포함하는 폴리헤드린 유전자 또는 그 일부분인 제조방법.
  4. 제3항에 있어서, 선택유전자 또는 그부분이 폴리헤드린 합성암호의 DNA배열의 최소한 일부분에 대치되어 클로닝 운반자내로 삽입되는 제조방법.
  5. 제1항에 있어서, 벡큘로비루스가 10Ｋ 프로모토를 포함하는 10Ｋ 유전자 또는 그것의 일부분인 제조방법.
  6. 제1항에 있어서, 벡큘로비루스가 오토그래파 캘리포리카(Autographa californica), 트리코프루시아(Trichoplusia ni), 라치프루시아오우(Rachiplusia ou), 또는 갈레리아 멜로넬라(Galleria mellonella)인 제조방법,
  7. 제1항에 있어서, 벡큘로비루스가 오토그래파 캘리포리카(Autographa californica)인 제조방법.
  8. 벡큘로비루스 유전자 또는 그부분을 포함하는 DNA 분체(단편)을 제조하기 위하여 벡큘로비루스 DNA를 절단하고 벡큘로비루스 유전자 전이벡터를 제조하기 위하여 상기 DNA 단편을 클로닝운반자로 삽입시키고 최소한 하나의 선택유전자 또는 그부분을 상기 벡큘로비루스 유전자 전이벡터내로 삽입시켜 그유전자 또는 그부분이 벡큘로비루스프로모터 또는 그 자신이 프로모터의 전사조절을 받는 것을 특징으로 하는, 벡큘로비루스 제놈대로 유도된 최소한 하나의 선택유전자 또는 그 부분을 가지고 재조합 전이벡터의 제조방법.
  9. 제8항에 있어서, 선택유전자 또는 그부분이 벡큘로비루스의 최소한 일부분에 대치되어 클로닝 운반자내로 삽입되는 제조방법.
  10. 제8항에 있어서, 벡큘로비루스유전자가 폴리헤드린 프로모터를 포함하는 폴리헤드린 유전자 또는 그 부분인 제조방법.
  11. 제10항에 있어서, 선택유전자 또는 그부분이 폴리헤드린 합성암호의 DNA배열의 최소한 일부분에 대치되어 클로닝 운반자내로 삽입되는 방법.
  12. 제8항에 있어서, 벡큘로비루스가 10Ｋ 프로모토를 포함하는 10Ｋ 유전자 또는 그 일부분인 제조방법.
  13. 제8항에 있어서, 벡큘로비루스가 오토그래파 캘리포리카(Autographa californica), 트리코프루시아니(Trichoplusia ni), 라치프루시아오우(Rachiplusia on), 또는 갈레리아 멜로넬라(Golleria mellonella)인 제조방법,
  14. 제8항에 있어서, 벡큘로비루스가 오토그래파 캘리포리카(Autographa californica)인 제조방법.
  15. 최소한 하나의 프로모터를 포함하는 DNA 분체(단편)를 제조하기 위하여 벡큘로비루스 DNA를 절단하고 선택유전자 또는 그 부분을 클로닝 할 수 있는 최소한 하나의 유부위를 가지는 변형클로닝 운반자를 제조하기 위하여 상기 분체를 클로닝 운반자재로 삽입시키는 것으로, 상기 유용클로닝 부위는 선택유전자 또는 그부분이 상기 프로모터의 전사조절하에 있도록 위치하는 것을 특징으로 하는 벡큘로비루스 유전자 조작의 중간 운반자로서 이용될 수 있는 벡큘로비루스전이 벡터 제조방법.
  16. 제15항에 있어서 벡큘로비루스유전자가 폴리헤드린 프로모터를 함유하는 폴리헤드린 유전자 또는 그 일부분인 제조방법.
  17. 제15항에 있어서, 벡큘로비루스 유전자가 10Ｋ 프로모토를 포함하는 10Ｋ 유전자 또는 그 일부분인 제조방법.
  18. 제15항에 있어서, 벡큘로비루스가 오토그래파 캘리포니아, 트리코프루시아니, 라치프루시아오우 또는 갈레리아 멜로넬라인 제조방법.
  19. 제15항에 있어서, 벡큘로비루스가 오토그래파 캘리포니카인 제조방법.
  20. 민감성 숙주 곤충세포를 재조합 벡큘로비루스 표현벡터와 감염시키고 상기 표현벡터는 최소한 하나의 선택유전자 또는 그부분을 포함하는 재조합 벡큘로비루스 제놈이며, 상기 선택유전 또는 그부분은 벡큘로루스 또는 그자신의 프로모터의 전사조절하에 존재하는 것을 특징으로 하는 선택폴리펩티드의 합성방법.
  21. 제20항에 있어서, 벡큘로비루스 프로모터가 폴리헤드린 프로모터인 제조방법.
  22. 제20항에 있어서, 벡큘로비루스 프로모토가 10Ｋ 프로모터인 제조방법.
  23. 표현벡터가 최소한 하나의 선택유전자 또는 그부분을 포함하는 벡큘로비루스 제놈이며, 선택유전자 또는 그 부분은 벡큘로비루스프로모터 또는 그 자신의 프로모터의 전사조절하에 존재하는 숙주곤충 세포에서 선택유전자 또는 그부분을 표현할 수 있는 재조합 벡큘로 표현벡터.
  24. 제23항에 있어서, 벡큘로비루스 프로모터가 폴리헤드린 프로모터인 재조합 벡큘로비루스 표현벡터.
  25. 제23항에 있어서, 벡큘로비루스 프로모토가 10Ｋ 프로모터인 재조합 벡큘로비루스 표현벡터.
  26. 벡큘로비루스 유전자와 그 유전자에 결합한 최소한 하나의 선택유전자 또는 그부분을 포함하고 상기 유전자 또는 그부분은 상기 벡큘로비루스 유전자 또는 그 자신의 유전자의 프로모터의 전사조절하에 존재하는 DNA 배열을 갖는 클로닝 운반자를 특징으로 하는, 선택유전자 또는 그부분을 벡큘로비루스 제놈내로 도입시킬 수 있는 재조합 전이벡터.
  27. 제26항에 있어서, 벡큘로비루스 프로모터가 폴리헤드린 프로모터인 재조합 전이벡터.
  28. 제26항에 있어서, 벡큘로비루스 프로모토가 10Ｋ 프로모터인 재조합 전이벡터.
  29. 벡큘로비루스 전이벡터가 벡큘로비루스 프로모토 유전자와 선택유전자 또는 그부분을 클로닝하는 최소한 하나의 유용부위를 포함하고, 선택유전자 또는 그부분이 상기 유용클로닝 부위로 삽입될 때 벡큘로비루스 프로모터의 전사조절하에 존재하도록 상기 유용클로닝 부위가 존재하는, 벡큘로비루스의 유전자 조작을 위한 중간 운반자로서 사용될 수 있는 벡큘로비루스 전이벡터.
  30. 제29항에 있어서, 벡큘로비루스 프로모터가 폴리헤드린 프로모터인 벡큘로비루스 전이벡터.
  31. 제29항에 있어서, NRRL B－15428 또는 NRRL B－155778로 지칭되는 벡큘로비루스 전이벡터.
  32. 제29항에 있어서, 벡큘로비루스 프로모토가 10Ｋ 프로모터인 벡큘로비루스 전이벡터.
  33. ※ 참고사항 : 최초출원내용에 의하여 공개하는 것임.
KR1019840002931A 1983-05-27 1984-05-28 재조합 벡큘로비루스 형질발현 벡터의 제조방법 KR910009203B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1019900001372A KR920001368B1 (ko) 1983-05-27 1990-02-03 재조합 벡큘로비루스 전이 벡터의 제조방법

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US498,856 1983-05-27
US06/498,858 US4745051A (en) 1983-05-27 1983-05-27 Method for producing a recombinant baculovirus expression vector
US498858 1983-05-27
US60969784A 1984-05-16 1984-05-16
US609694 1984-05-16

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1019900001372A Division KR920001368B1 (ko) 1983-05-27 1990-02-03 재조합 벡큘로비루스 전이 벡터의 제조방법

Publications (2)

Publication Number Publication Date
KR840008818A true KR840008818A (ko) 1984-12-19
KR910009203B1 KR910009203B1 (ko) 1991-11-04

Family

ID=27052974

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019840002931A KR910009203B1 (ko) 1983-05-27 1984-05-28 재조합 벡큘로비루스 형질발현 벡터의 제조방법

Country Status (17)

Country Link
EP (1) EP0127839B1 (ko)
JP (2) JPH0779700B2 (ko)
KR (1) KR910009203B1 (ko)
AT (1) ATE78293T1 (ko)
AU (1) AU581174B2 (ko)
BR (1) BR8402666A (ko)
CA (1) CA1222213A (ko)
DE (1) DE3485810T2 (ko)
DK (1) DK172401B1 (ko)
ES (1) ES532825A0 (ko)
IE (1) IE58011B1 (ko)
IL (1) IL71906A (ko)
IN (1) IN160416B (ko)
MX (1) MX164250B (ko)
NO (1) NO173944C (ko)
NZ (1) NZ208259A (ko)
PH (1) PH25395A (ko)

Families Citing this family (148)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1984002077A1 (en) * 1982-11-30 1984-06-07 Us Health Process for producing poxvirus recombinants for expression of foreign genes
JPS619288A (ja) * 1984-06-21 1986-01-16 Dai Ichi Seiyaku Co Ltd ペプチド類の製法
US5004687A (en) * 1985-05-21 1991-04-02 University Of Georgia Research Foundation, Inc. Insect virus vector with broadened host range
GB8521496D0 (en) * 1985-08-29 1985-10-02 Ciba Geigy Ag Repressible yeast promoters
FR2593519B1 (fr) * 1985-09-25 1994-01-07 Oncogen Vaccin contre le syndrome immunodeficitaire acquis et intermediaires pour la preparation de ce vaccin
GR862412B (en) * 1985-09-25 1987-01-23 Oncogen Vaccines and immuinoassays for acquired immune deficiency syndrome
IL80529A0 (en) * 1985-11-14 1987-02-27 Daiichi Seiyaku Co Method of producing peptides
JPS63167797A (ja) * 1985-12-18 1988-07-11 マイクロジエネシス，インコ−ポレイテイド 選択された昆虫宿主細胞中で選択されたポリペプチドを製造する方法
NZ221702A (en) * 1986-09-08 1989-02-24 Bishop David H L Expression of human hepatitis b antigens in insects and cultured insect cells using recombinant baculoviruses
US5071748A (en) * 1986-09-09 1991-12-10 Genetics Institute, Inc. Mixed baculovirus compositions and uses thereof
IE872748L (en) * 1986-10-16 1988-04-16 Arjomari Europ Polypeptides derived from the evvelope gene of human¹immunodeficiency virus in recombinant baculovirus infected¹insect cells
WO1988005081A2 (en) * 1986-12-30 1988-07-14 Cetus Corporation Novel plasminogen activator
US5041379A (en) * 1987-03-16 1991-08-20 American Biogenetic Science, Inc. Heliothis expression systems
WO1988007082A1 (en) * 1987-03-16 1988-09-22 American Biogenetic Sciences, Inc. Recombinant baculovirus occlusion bodies in vaccines and biological insecticides
JPS6463395A (en) * 1987-05-04 1989-03-09 Oncogen Oncostatin m and novel composition having antitumor activity
EP0364492A1 (en) * 1987-06-30 1990-04-25 The Upjohn Company Virus proteins having reduced o-linked glycosylation
AU2136788A (en) * 1987-07-24 1989-03-01 Cetus Corporation Production of ricin toxins in a baculovirus-insect cell expression system
US5372943A (en) * 1987-07-24 1994-12-13 Cetus Corporation Lipid microemulsions for culture media
AU2251488A (en) * 1987-07-24 1989-03-01 Cetus Corporation Production of biologically active forms of csf using a baculovirus (acnpv)-insect cell expression system
US5024947A (en) * 1987-07-24 1991-06-18 Cetus Corporation Serum free media for the growth on insect cells and expression of products thereby
US5443964A (en) * 1987-08-10 1995-08-22 Duke University Poxvirus insertion/expression vector
US5578468A (en) * 1987-08-10 1996-11-26 Duke University Site-specific RNA cleavage
US5876962A (en) * 1987-08-12 1999-03-02 Natural Environment Research Council Expression vectors for the synthesis of proteins and plasmid replicons and sequence cassettes for use in constructing such vectors
GB8810808D0 (en) * 1988-05-06 1988-06-08 Wellcome Found Vectors
JP2511494B2 (ja) * 1988-05-12 1996-06-26 善治 松浦 日本脳炎ウイルス表面抗原蛋白質の製造法
FR2631974B1 (fr) * 1988-05-31 1992-12-11 Agronomique Inst Nat Rech Baculovirus modifie, son procede de preparation et son application en tant que vecteur d'expression de genes
US5763573A (en) * 1988-08-10 1998-06-09 Chiron Corporation GTPase activating protein fragments
US5760203A (en) * 1988-08-10 1998-06-02 Chiron Corporation Gap gene sequences
DE68912248T2 (de) * 1988-09-16 1994-05-26 Sandoz Ag Diuretischer Faktor.
US5272063A (en) * 1988-11-22 1993-12-21 Syntex (U.S.A.) Inc. Process of making human nerve growth factor
US5145775A (en) * 1989-02-28 1992-09-08 Research Association For Biotechnology Of Agricultural Chemicals Polyhedrin gene and genetic engineering thereof
GB8910962D0 (en) * 1989-05-12 1989-06-28 Natural Environment Res Novel baculovirus expression vectors and use thereof in the expression of foreign proteins in insects or insect cells
US5294548A (en) * 1990-04-02 1994-03-15 American Biogenetic Sciences, Inc Recombianant Hepatitis a virus
FR2664905B1 (fr) * 1990-07-18 1994-08-12 Agronomique Inst Nat Rech Baculovirus modifie, son procede d'obtention, et vecteurs d'expression obtenus a partir dudit baculovirus.
GB9106185D0 (en) * 1991-03-22 1991-05-08 Wellcome Found Biological control agents
WO1993006224A1 (en) * 1991-09-18 1993-04-01 Hong Kong Tech Company Limited Expression vector and silkworm larvae transformant containing the same
IT1259042B (it) * 1992-01-27 1996-03-11 Mini Ricerca Scient Tecnolog Preparazione di vettori di espressione per la sintesi del polipeptide chiamato fattore osteogenetico op-1 in cellule eucariotiche di spodoptera frugiperda via infezione con baculovirus ricombinante
ES2048646B1 (es) * 1992-04-15 1994-10-01 Ercros Sa Procedimiento para la obtencion de la proteina vp2 del virus de la peste equina africana (ahsv)
CA2179394A1 (en) 1993-12-23 1995-06-29 Kostas Iatrou Methods of expressing proteins in insect cells and methods of killing insects
US5629167A (en) 1994-04-19 1997-05-13 Biocine S.P.A. Detection of antibodies against Chlamydia trachomatis pgp3 antigen in patient sera by enzyme-linked immunosorbent assay
US5952210A (en) * 1994-06-03 1999-09-14 G. D. Searle & Company Nucleic acids and expression vectors encoding human leukotiene C4 synthase
JP2640623B2 (ja) * 1994-06-10 1997-08-13 日本製粉株式会社 ターミナルデオキシヌクレオチジルトランスフェラーゼの製造方法
ES2125530T3 (es) * 1994-07-29 1999-03-01 Teijin Ltd Secuencia de acidos nucleicos que codifica una enzima semejante a tripsina y procedimiento para producir la enzima.
JP2565668B2 (ja) * 1995-01-17 1996-12-18 第一製薬株式会社 ペプチド類の製造用ベクター
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
AU736334B2 (en) * 1997-03-27 2001-07-26 University Of British Columbia, The Insect expression vectors
ATE505478T1 (de) 1997-08-27 2011-04-15 Novartis Vaccines & Diagnostic Molekular-mimetika von meningokokkalen b epitopen
CA2308606A1 (en) 1997-11-06 1999-05-20 Chiron S.P.A. Neisserial antigens
DE69941567D1 (de) 1998-01-14 2009-12-03 Novartis Vaccines & Diagnostic Antigene aus neisseria meningitidis
GB9808932D0 (en) 1998-04-27 1998-06-24 Chiron Spa Polyepitope carrier protein
CN101293920B (zh) 1998-05-01 2012-07-18 诺华疫苗和诊断公司 脑膜炎奈瑟球菌抗原和组合物
EP1121437B1 (en) 1998-10-15 2008-02-20 Novartis Vaccines and Diagnostics, Inc. Metastatic breast and colon cancer regulated genes
AU2367600A (en) 1998-12-16 2000-07-03 Chiron Corporation Human cyclin-dependent kinase ((hpnqalre))
NZ530640A (en) 1999-04-30 2006-06-30 Chiron S Conserved neisserial antigens
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
JP2003527833A (ja) 1999-10-14 2003-09-24 クロンテック・ラボラトリーズ・インコーポレーテッド 花虫類に由来する発色団／蛍光体、およびそれらの使用法
AU784203B2 (en) 1999-10-29 2006-02-23 Glaxosmithkline Biologicals S.A. Neisserial antigenic peptides
EP1985701B1 (en) 2000-01-10 2012-05-30 Novartis Vaccines and Diagnostics, Inc. Genes differentially expressed in breast cancer
RU2279889C2 (ru) 2000-01-17 2006-07-20 Чирон С.Р.Л. ВАКЦИНА ВЕЗИКУЛ НАРУЖНЫХ МЕМБРАН (OMV), СОДЕРЖАЩАЯ БЕЛКИ НАРУЖНОЙ МЕБРАНЫ N.Meningitidis СЕРОЛОГИЧЕСКОЙ ГРУППЫ В
US7939087B2 (en) 2000-10-27 2011-05-10 Novartis Vaccines And Diagnostics, Inc. Nucleic acids and proteins from Streptococcus groups A & B
DE10112825A1 (de) 2001-03-16 2002-10-02 Fresenius Kabi De Gmbh HESylierung von Wirkstoffen in wässriger Lösung
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
WO2002081639A2 (en) 2001-04-06 2002-10-17 Georgetown University Gene brcc2 and diagnostic and therapeutic uses thereof
AU2002258728A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene brcc-3 and diagnostic and therapeutic uses thereof
AU2002305151A1 (en) 2001-04-06 2002-10-21 Georgetown University Gene scc-112 and diagnostic and therapeutic uses thereof
JP4413617B2 (ja) 2001-12-12 2010-02-10 カイロン ソチエタ ア レスポンサビリタ リミタータ Ｃｈｌａｍｙｄｉａｔｒａｃｈｏｍａｔｉｓに対する免疫化
JP4700281B2 (ja) 2001-12-19 2011-06-15 ザ・ユニバーシティ・オブ・シカゴ 急速に成熟する蛍光タンパク質およびその使用法
DE10209821A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung von Proteinen an ein modifiziertes Polysaccharid
DE10209822A1 (de) 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
US7138512B2 (en) 2002-04-10 2006-11-21 Georgetown University Gene SHINC-2 and diagnostic and therapeutic uses thereof
US7244565B2 (en) 2002-04-10 2007-07-17 Georgetown University Gene shinc-3 and diagnostic and therapeutic uses thereof
AU2003239865A1 (en) 2002-05-24 2003-12-12 Restoragen Inc. Method for universal enzymatic production of bioactive peptides
AU2003243316A1 (en) 2002-05-24 2003-12-12 Nps Allelix Corp. Method for enzymatic production of glp-2(1-33) and glp-2-(1-34) peptides
RU2329274C2 (ru) 2002-09-11 2008-07-20 Фрезениус Каби Дойчланд Гмбх Способ получения производных гидроксиалкилкрахмала
ES2314238T3 (es) 2002-10-08 2009-03-16 Fresenius Kabi Deutschland Gmbh Conjugados de oligosacaridos farmaceuticamente activos.
AU2003288660A1 (en) 2002-11-15 2004-06-15 Chiron Srl Unexpected surface proteins in neisseria meningitidis
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
WO2005014655A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
EP1670947B1 (en) 2003-09-23 2015-04-01 University Of North Carolina At Chapel Hill Methods and compositions for the correlation of single nucleotide polymorphisms in the vitamin k epoxide reductase gene and warfarin dosage
JP4777251B2 (ja) 2003-10-14 2011-09-21 バクスター・インターナショナル・インコーポレイテッド ビタミンｋエポキシド還元酵素複合体サブユニット１ｖｋｏｒｃ１、クマリンおよびその誘導体の治療標的
SI1704234T1 (sl) 2003-11-21 2012-08-31 Nps Pharma Inc Proizvodnja glukagonu podobnih peptidov 2 in analogov
CA2553040A1 (en) 2004-02-02 2005-08-18 Ambrx, Inc. Modified human four helical bundle polypeptides and their uses
EP1732609B1 (en) 2004-03-11 2012-07-11 Fresenius Kabi Deutschland GmbH Conjugates of hydroxyalkyl starch and a protein
TWI417303B (zh) 2004-03-11 2013-12-01 Fresenius Kabi De Gmbh 經由還原胺化作用製得之羥烷基澱粉及蛋白質的接合物
US8268324B2 (en) 2004-03-29 2012-09-18 Galpharma Co., Ltd. Modified galectin 9 proteins and use thereof
US7250298B2 (en) 2004-04-07 2007-07-31 The University Of Chicago Monomeric red fluorescent proteins
CN102603895B (zh) 2004-06-18 2016-09-28 Ambrx公司 新颖抗原结合多肽和其用途
KR20070090023A (ko) 2004-12-22 2007-09-04 암브룩스, 인코포레이티드 변형 인간 성장 호르몬
US7385028B2 (en) 2004-12-22 2008-06-10 Ambrx, Inc Derivatization of non-natural amino acids and polypeptides
JP2008532544A (ja) 2005-03-15 2008-08-21 ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 活性ビタミンｋ依存性タンパク質を生産するための方法及び組成物
KR101447897B1 (ko) 2005-03-21 2014-10-07 비로베이, 인코포레이티드 시스테인 단백질분해효소 억제제로서의 알파 케토아미드화합물
EP3214095B1 (en) 2005-05-12 2019-12-11 ZymoGenetics, Inc. Compositions and methods for modulating immune responses
CN101300346B (zh) 2005-06-24 2013-04-24 帝人制药株式会社 新型生理物质nesfatin及其相关物质、以及它们的用途
EP1762250A1 (en) 2005-09-12 2007-03-14 Fresenius Kabi Deutschland GmbH Conjugates of hydroxyalkyl starch and an active substance, prepared by chemical ligation via thiazolidine
DE102005048898A1 (de) 2005-10-12 2007-04-19 Sanofi-Aventis Deutschland Gmbh EGLN2-Varianten und ihre Verwendung bei der Vorbeugung oder Behandlung thromboembolischer Erkrankungen und koronarer Herzerkrankungen
US7749704B2 (en) 2005-11-01 2010-07-06 Mayo Foundation For Medical Education And Research Promoter polymorphisms of the BLyS gene and use in diagnostic methods
KR20080079643A (ko) 2005-11-16 2008-09-01 암브룩스, 인코포레이티드 비-천연 아미노산을 포함하는 방법 및 조성물
US20100015168A1 (en) 2006-06-09 2010-01-21 Novartis Ag Immunogenic compositions for streptococcus agalactiae
EP2069396B1 (en) 2006-09-08 2015-10-21 Ambrx, Inc. Modified human plasma polypeptide or fc scaffolds and their uses
US7985783B2 (en) 2006-09-21 2011-07-26 The Regents Of The University Of California Aldehyde tags, uses thereof in site-specific protein modification
DE102006058373A1 (de) 2006-12-08 2008-06-12 Evocatal Gmbh (R)-Hydroxynitril-Lyase aus Brassicaceen
DE102007014742A1 (de) 2007-03-23 2008-09-25 Evonik Degussa Gmbh Isoformen der Schweineleber Esterase
CN104163864B (zh) 2007-03-30 2017-08-01 Ambrx公司 经修饰fgf‑21多肽和其用途
AU2008308509B2 (en) 2007-10-04 2014-10-23 Zymogenetics, Inc. B7 family member zB7H6 and related compositions and methods
WO2009059305A2 (en) 2007-11-01 2009-05-07 The University Of Chicago Red fluorescent proteins with enhanced bacterial expression, increased brightness and reduced aggregation
MX338336B (es) 2007-11-20 2016-04-07 Ambrx Inc Polipeptidos de insulina modificados y sus usos.
WO2009073511A2 (en) 2007-11-30 2009-06-11 Mayo Foundation For Medical Education And Research Polymorphisms of the blys gene and use in diagnostic methods
EP2070950A1 (en) 2007-12-14 2009-06-17 Fresenius Kabi Deutschland GmbH Hydroxyalkyl starch derivatives and process for their preparation
CN101939443B (zh) 2008-02-08 2014-01-29 Ambrx公司 经修饰瘦素多肽和其用途
PT2318029T (pt) 2008-07-23 2018-01-10 Ambrx Inc Polipéptidos de g-csf bovino modificados e suas utilizações
EP2342223B1 (en) 2008-09-26 2017-04-26 Ambrx, Inc. Modified animal erythropoietin polypeptides and their uses
ES2660000T3 (es) 2008-09-26 2018-03-20 Ambrx, Inc. Vacunas y microorganismos dependientes de la replicación de aminoácidos no naturales
DE102009007272A1 (de) 2009-02-03 2010-08-05 Evocatal Gmbh Alkoholdehydrogenase aus Gluconobacter oxydans und deren Verwendung
EP2292781A1 (en) 2009-08-17 2011-03-09 Genethon Baculovirus-based production of biopharmaceuticals free of contaminating baculoviral virions
EP2333074A1 (en) 2009-12-14 2011-06-15 Robert Steinfeld Substances and methods for the treatment of lysosmal storage diseases
US20120283171A1 (en) 2009-12-21 2012-11-08 Ambrx, Inc. Modified bovine somatotropin polypeptides and their uses
SG181769A1 (en) 2009-12-21 2012-07-30 Ambrx Inc Modified porcine somatotropin polypeptides and their uses
US20120023226A1 (en) * 2010-07-26 2012-01-26 Steve Petersen Prediction of activity session for mobile network use optimization and user experience enhancement
PL2605789T3 (pl) 2010-08-17 2019-11-29 Ambrx Inc Zmodyfikowane polipeptydy relaksyny i ich zastosowania
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
AR083006A1 (es) 2010-09-23 2013-01-23 Lilly Co Eli Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
US9631002B2 (en) 2010-12-21 2017-04-25 The University Of North Carolina At Chapel Hill Methods and compositions for producing active vitamin K-dependent proteins
WO2013014294A2 (en) 2011-07-27 2013-01-31 Genethon Improved baculovirus expression systems
DK3044231T3 (da) 2013-09-12 2020-09-07 Biomarin Pharm Inc Aav-vektorer, der omfatter en genkodningsfaktor viii primær anmodning
KR20240024362A (ko) 2014-10-24 2024-02-23 브리스톨-마이어스 스큅 컴퍼니 변형된 fgf-21 폴리펩티드 및 그의 용도
RU2020126034A (ru) 2015-09-24 2020-09-02 Байомарин Фармасьютикал Инк. Векторы фактора fviii на основе аденоассоциированных вирусов, соответствующие вирусные частицы и содержащие их терапевтические композиции
TN2018000163A1 (en) 2015-11-12 2019-10-04 Res Inst Nationwide Childrens Hospital Methods of treating muscular dystrophy
EP3222712A1 (en) 2016-03-22 2017-09-27 Universität zu Köln Alcohol dehydrogenase from pichia pastoris and use thereof
SG11201811603WA (en) 2016-07-26 2019-02-27 Biomarin Pharm Inc Novel adeno-associated virus capsid proteins
SG10201912034UA (en) 2017-02-08 2020-02-27 Bristol Myers Squibb Co Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
EP3688014A4 (en) 2017-09-29 2020-09-16 Massachusetts Eye and Ear Infirmary PRODUCTION OF ADENO-ASSOCIATED VIRUSES IN INSECT CELLS
EP3790627A2 (en) 2018-05-09 2021-03-17 BioMarin Pharmaceutical Inc. Methods of treating phenylketonuria
KR20210008491A (ko) 2018-05-14 2021-01-22 바이오마린 파머수티컬 인크. 청소년 대상체에서 aav 벡터의 안정한 발현
TW202005978A (zh) 2018-05-14 2020-02-01 美商拜奧馬林製藥公司 新穎肝靶向腺相關病毒載體
EP3969061A1 (en) 2019-05-14 2022-03-23 BioMarin Pharmaceutical Inc. Methods of redosing gene therapy vectors
KR20220066164A (ko) 2019-09-27 2022-05-23 바이오마린 파머수티컬 인크. 크기 배제 크로마토그래피 및 다각도 광 산란 기술을 사용한 유전자 치료 바이러스 입자의 특성화
EP4058475A1 (en) 2019-11-14 2022-09-21 BioMarin Pharmaceutical Inc. Treatment of hereditary angioedema with liver-specific gene therapy vectors
US20230075854A1 (en) 2020-02-10 2023-03-09 Biomarin Pharmaceutical Inc. Virus-free cell cultures
WO2021183895A1 (en) 2020-03-13 2021-09-16 Biomarin Pharmaceutical Inc. Treatment of fabry disease with aav gene therapy vectors
AR122409A1 (es) 2020-04-03 2022-09-07 Biomarin Pharm Inc Tratamiento de la fenilcetonuria con aav y formulaciones terapéuticas
WO2021236908A2 (en) 2020-05-20 2021-11-25 Biomarin Pharmaceutical Inc. Use of regulatory proteins for the production of adeno-associated virus
JP2023548067A (ja) 2020-11-02 2023-11-15 バイオマリン ファーマシューティカル インコーポレイテッド アデノ随伴ウイルスを濃縮するためのプロセス
EP4408481A2 (en) 2021-10-01 2024-08-07 BioMarin Pharmaceutical Inc. Treatment of hereditary angioedema with aav gene therapy vectors and therapeutic formulations
TW202421788A (zh) 2022-09-22 2024-06-01 美商拜奧馬林製藥公司 用ａａｖ基因療法載體治療致心律不整性心肌病
TW202417631A (zh) 2022-09-22 2024-05-01 美商拜奧馬林製藥公司 用ａａｖ基因治療載體治療心肌病
WO2024151568A1 (en) 2023-01-09 2024-07-18 Biomarin Pharmaceutical Inc. Epigenetic modifiers improve aav gene therapy durability

Also Published As

Publication number Publication date
JPH0799989A (ja) 1995-04-18
NO173944B (no) 1993-11-15
DE3485810T2 (de) 1992-12-10
ATE78293T1 (de) 1992-08-15
DK257984D0 (da) 1984-05-25
DE3485810D1 (de) 1992-08-20
EP0127839A3 (en) 1986-06-25
DK172401B1 (da) 1998-05-18
EP0127839B1 (en) 1992-07-15
ES8507176A1 (es) 1985-08-16
PH25395A (en) 1991-06-03
IE58011B1 (en) 1993-06-16
KR910009203B1 (ko) 1991-11-04
JPH0779700B2 (ja) 1995-08-30
MX164250B (es) 1992-07-27
ES532825A0 (es) 1985-08-16
DK257984A (da) 1984-11-28
NO842094L (no) 1984-11-28
IL71906A (en) 1992-08-18
EP0127839A2 (en) 1984-12-12
JPS6037988A (ja) 1985-02-27
IE841269L (en) 1984-11-27
IN160416B (ko) 1987-07-11
AU2871784A (en) 1984-11-29
CA1222213A (en) 1987-05-26
NZ208259A (en) 1988-01-08
JP2644447B2 (ja) 1997-08-25
NO173944C (no) 1994-02-23
IL71906A0 (en) 1984-09-30
AU581174B2 (en) 1989-02-16
BR8402666A (pt) 1985-05-07

Similar Documents

Publication Publication Date Title
KR840008818A (ko) 재조합 벡큘로비루스 표현 벡터의 제조방법
Tessier et al. Enhanced secretion from insect cells of a foreign protein fused to the honeybee melittin signal peptide
KR850005499A (ko) Dna 재조합 기술에 의한 폴리펩타이드의 제조방법
PT90687A (pt) Baculovirus modificado, processo para a sua preparacao e sua aplicacao como vector de expressao de genes
de A. Zanotto et al. The Anticarsia gemmatalis nuclear polyhedrosis virus polyhedrin gene region: sequence analysis, gene product and structural comparisons
WO2002020748A8 (de) Wirtszellen zur verpackung von rekombinantem adeno-assoziiertem virus (raav), verfahren zu ihrer herstellung und deren verwendung
Mori et al. Transovarian transmission of a foreign gene in the silkworm, Bombyx mori, by Autographa californica nuclear polyhedrosis virus
Crook et al. Comprehensive physical map of the Cydia pomonella granulovirus genome and sequence analysis of the granulin gene region
Dasgupta et al. Nucleotide sequences of three Nodavirus RNA2's: the messengers for their coat protein precursors.
Li et al. Characterization of a baculovirus alkaline nuclease
KR910001058A (ko) 고양이 인터페론 및 이의 제조방법
Liu et al. Identification, Molecular Cloning, and Transcription Analysis of theChoristoneura fumiferanaNuclear Polyhedrosis VirusSpindle-like ProteinGene
KR970705923A (ko) LERK-6으로 명명된 시토킨(Cytokine Designated LERK-6)
Lu et al. Reduced expression of the immediate-early protein IE0 enables efficient replication of Autographa californica multiple nucleopolyhedrovirus in poorly permissive Spodoptera littoralis cells
KR860004145A (ko) 재조합 벡큘로비루스 표현 벡터의 제조방법
Sridhar et al. Baculovirus vector-mediated expression of heterologous genes in insect cells
Echeverry et al. Sequence analysis and expression of the polyhedrin gene of Choristoneura fumiferana cytoplasmic polyhedrosis virus (CfCPV)
KR890701745A (ko) O-결합 글리코실화가 감소된 바이러스 단백질
Hashimoto et al. Physical mapping of Bombyx mori nuclear polyhedrosis virus strain D1: identification of novel interspersed homologous regions
MURAO et al. Genomic rearrangement in genome segment 12 of rice dwarf phytoreovirus
Marín et al. Characterization of Gandalf, a new inverted-repeat transposable element of Drosophila koepferae
Kool et al. Nucleotide sequence and genetic organization of a 7.3 kb region (map unit 47 to 52.5) of Autographa californica nuclear polyhedrosis virus fragment Eco RI-C
KR950005993A (ko) 씨(c)형 간염바이러스의 이2(e2) 단백질 유전자의 베큘로바이러스 발현 벡터 및 이를 이용한 이2(e2) 단백질의 제조방법
KR950005994A (ko) 곤충세포를 이용한 씨(C)형 간염바이러스의 핵(Core22) 단백질의 제조
US7084254B2 (en) Ti-4 protein derived from Triatoma infestans exhibiting activity to inhibit platelet aggregation

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application
E902 Notification of reason for refusal
J2X1 Appeal (before the patent court)

Free format text: APPEAL AGAINST DECISION TO DECLINE REFUSAL

G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20031022

Year of fee payment: 13

EXPY Expiration of term